Sunday, August 1, 2021

89bio gets green light to take liquid NASH prospect into phase 2

89bio is set to take a liquid formulation of its nonalcoholic steatohepatitis (NASH) candidate into a phase 2b clinical trial after reaching an agreement with the FDA. The new formulation is intended to provide patients with a more convenient administration method that supports compliance.  

San Francisco-based 89bio took a frozen liquid formulation of its glycoPEGylated analog of FGF21 into human testing while working on an alternative that is better suited to larger trials and real-world use. The transition to the new formulation took a step forward this week when 89bio disclosed written guidance from the FDA that includes agreement on the use of the liquid product in a phase 2b trial.

“We believe the liquid formulation will provide a more convenient administration method which we know is critical for compliance for patients living with chronic conditions like NASH,” 89bio CEO Rohan Palekar said in a statement.

The development of a liquid formulation is part of a broader, ongoing effort to provide patients with convenient ways of administering BIO89-100. 89bio has also previously disclosed development of a freeze-dried formulation and work on a prefilled syringe. The biotech also plans to develop a pen-type auto-injector formulation.

That range of formulation and administration options could prove useful if 89bio needs to compete for the NASH market with developers of similar drugs. Akero Therapeutics and Bristol Myers Squibb are developing rival FGF21 analogs that will, respectively, be provided in lyophilized and liquid forms if they come to market.

89bio is taking its challenger into phase 2b on the strength of clinical data it frames as giving it an edge over the competition. The phase 1b/2a study linked BIO89-100 to significant declines in liver fat that were comparable to the results reported by Akero but free from some of the adverse events associated with that rival candidate. 

Source link

Stay Connected


Latest Articles

Need to create vigilance and awareness on zoonotic diseases: India’s Health Minister

The COVID-19 pandemic has highlighted the need of creating vigilance and awareness on zoonotic diseases, informed Union Health Minister Mansukh Mandaviya while virtually inaugurating...

Covid’s second wave proves lethal for pregnant women

At SVP Hospital in Ahmedabad – one of the major Covid-19 hospitals of the city – 148 pregnant women with Covid-19 infection were admitted...

7 Tips to Keep Your Gut Healthy

This is common to say health (and illness) starts in your gut. If you have poor gut health, you’ll experience anything from wrinkled skin, to...

SII making first batch of Covovax: Poonawalla

The first batch of Covovax, a Covid-19 vaccine developed by Novavax Inc, is being manufactured at the Serum Institute of India's Pune facility, SII...

Sputnik V is safest among all Covid-19 vaccines, no deaths recorded: Buenos Aires study

A study by the Buenos Aires Ministry of Health to monitor the safety of the Sputnik V vaccine against Covid-19 confirmed on Thursday that...